Dishman Carbogen Amcis fell 2.32% to Rs 113.75 after a search and survey was carried out by the state income tax department on the company.
The officials of Income-Tax Department visited the company's head offices and manufacturing sites in connection with search under Section 142 of the Income-Tax Act on 19 December 2019 and search enquiry is continuing. The company said it is extending all co-operations in this regard.
The firm clarified that this has no impact on its routine operations. After conclusion, the company will be able to update the of any material information/event. The announcement was made after trading hours yesterday, 19 December 2019.
Dishman Carbogen Amcis' consolidated net profit declined 6.5% to Rs 41.16 crore on 4% rise in net sales to Rs 449.79 crore in Q2 September 2019 over Q2 September 2018.
Dishman Carbogen Amcis offers a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries at all stages of drug development.
The scrip extended losses for fourth straight sessions. The stock has corrected by 9.72% to currently trade at Rs 113.75 from a recent closing high of Rs 126 registered on 16 December 2019.
More From This Section
On the technical front, the stock's RSI (relative strength index) stood at 35.22. The RSI oscillates between zero and 100. Traditionally the RSI is considered overbought when above 70 and oversold when below 30.
The stock was currently trading below its 50-day moving average (DMA) placed at 124.31 as well as its 200 DMA placed at 186.99.
Powered by Capital Market - Live News